Artiva grants director Baker 16,250 stock options

A director of Artiva Biotherapeutics received a new option grant for 16,250 shares that fully vests by the 2027 annual stockholder meeting.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option grant on September 10, 2026 covering 16,250 shares of common stock at an exercise price of $10.42 per share. The option vests in full on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting and expires on September 9, 2036.

Insider Trade Summary

Grant/Award: 16,250 shares

Grant/Award 1 txn

Insider Baker Daniel G.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	16,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 16,250 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Option shares granted: 16,250 shares Exercise price: $10.42 per share Shares underlying option after grant: 16,250 shares +2 more

5 metrics

Option shares granted 16,250 shares Director stock option grant to Daniel G. Baker on September 10, 2026

Exercise price $10.42 per share Exercise price for the 16,250-share director stock option

Shares underlying option after grant 16,250 shares Total shares subject to the reported stock option following the transaction

Vesting date trigger September 10, 2027 Latest possible vesting date, or earlier on the 2027 annual stockholder meeting date

Option expiration date September 9, 2036 Expiration date of the director stock option grant

Key Terms

Director Stock Option, Common Stock, vesting, annual stockholder meeting

4 terms

Director Stock Option financial

"Director Stock Option (Right to Buy)"

Common Stock financial

"underlying security is designated as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual stockholder meeting financial

"the date of the Issuer's 2027 annual stockholder meeting."

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV report for director Daniel G. Baker?

ARTV reported that director Daniel G. Baker received a stock option grant for 16,250 shares of common stock on September 10, 2026, with an exercise price of $10.42 per share and expiration on September 9, 2036.

What are the vesting terms of Daniel G. Baker’s new ARTV stock options?

The option covering 16,250 shares of ARTV common stock will vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, according to the footnote disclosure.

What is the exercise price and expiry of the ARTV options granted to Daniel G. Baker?

The stock option granted to Daniel G. Baker has an exercise price of $10.42 per share and an expiration date of September 9, 2036, giving the right to purchase 16,250 shares of Artiva Biotherapeutics common stock.

Did Artiva Biotherapeutics indicate a Rule 10b5-1 trading plan for this ARTV Form 4?

No. The filing indicates that the transaction was not reported as being made under a Rule 10b5-1 trading plan, meaning there is no affirmed pre-arranged trading plan associated with this option grant.

How many ARTV shares may be acquired under Daniel G. Baker’s new option grant?

Under the reported option grant, Daniel G. Baker may acquire up to 16,250 shares of Artiva Biotherapeutics common stock upon exercise at the stated exercise price of $10.42 per share, subject to the vesting terms described in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:03 PM Accepted by SEC EDGAR 09/14/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baker Daniel G.

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.42	09/10/2026		A		16,250		(1)	09/09/2036	Common Stock	16,250	$0	16,250	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)